The weekly options data indicated that 26,000 is expected to be a crucial resistance zone, which was tested intraday on Wednesday, with immediate support at 25,900.
Experts expect the Nifty 50 to march toward the psychological 26,000 level, followed by the 26,200 zone in the upcoming sessions, as long as it holds the 25,800 support.
Section 1. Purpose. American-manufactured military equipment is the best in the world, resulting in American dominance across international defense exports. It is critical that the United States fully ...
Sign up for our newsletter about national security here. “At least,” a friend sighed, “they didn’t call it the 2026 National War Strategy.” True enough ...
This issue is preventing our website from loading properly. Please review the following troubleshooting tips or contact us at [email protected]. By submitting your ...
PythoC lets you use Python as a C code generator, but with more features and flexibility than Cython provides. Here’s a first look at the new C code generator for Python. Python and C share more than ...
President Trump released his national security strategy late Thursday night with a focus on building up a larger military presence in the Western Hemisphere, balancing global trade, tightening up ...
WASHINGTON — President Donald Trump's administration has set forth a new national security strategy that paints European allies as weak and aims to reassert America's dominance in the Western ...
This issue is preventing our website from loading properly. Please review the following troubleshooting tips or contact us at [email protected]. By submitting your ...
Introduction – What Is American Strategy? To ensure that America remains the world’s strongest, richest, most powerful, and most successful country for decades to come, our country needs a coherent, ...
The White House quietly released President Donald Trump’s new national security strategy late Thursday, a 33-page document that elevates his “America First” doctrine and sets out the administration’s ...
Management indicated plans to provide both regulatory and clinical trial updates on blarcamesine for indications beyond Alzheimer’s, including Parkinson’s disease, Rett syndrome, and Fragile X.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results